If you’ve ever suffered from eczema, you’ll know how uncomfortable, sore, and itchy it can be. This May is Eczema Awareness Month in Australia, giving a voice to the three million Aussies who were affected by eczema last year. Often debilitating, the skin condition can have a big impact on people’s lives. This Eczema Awareness […]
Watch out, Incyte. Leo Pharma and its JAK inhibitor cream delgocitinib are coming to disrupt the topical atopic dermatitis market, currently inhibited by Incyte’s approved Opzelura. With several positive studies in hand, including a recent phase 3 trial pitting the candidate against the current standard-of-care, Leo says its delgocitinib has growth driver potential. Now, the drugmaker […]
On April 29, 2024, The US Food and Drug Administration (FDA) has accepted a Supplemental New Drug Application for tapinarof cream, 1%, for the topical treatment of atopic dermatitis in adults and children aged ≥ 2 years, according to an announcement by the manufacturer, Dermavant Sciences. Tapinarof cream, 1% (VTAMA) is a steroid-free aryl hydrocarbon […]
At the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California, Melinda Gooderham, MSc, MD, FRCPC, presented late-breaking data on the long-term safety and efficacy of delgocitinib for moderate to severe chronic hand eczema (CHE).1 Patients who completed 16 weeks of treatment in DELTA 1 and DELTA 2 were then treated in […]